Responses

Download PDFPDF
Short report
Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses [https://authors.bmj.com/after-submitting/rapid-responses/].
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses [https://www.bmj.com/company/journals-terms-and-conditions-for-rapid-responses/] and understand that your personal data will be processed in accordance with those terms and our privacy notice [https://www.bmj.com/company/your-privacy/].
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Pain Responsiveness: A Useful Clinical Tool?
    • Hannah E. Silverman, Research Worker Taub Institute, Department of Neurology, Columbia University Irving Medical Center
    • Other Contributors:
      • Megan S. Barker, Postdoctoral Research Scientist in Neuropsychology
      • Masood Manoocheri, Staff Associate
      • Edward D. Huey, Psychiatrist

    The recently published paper ‘Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort’ by Convery et al.[1] draws attention to a topic of great importance in the field of frontotemporal dementia (FTD) research. In this study, Convery and colleagues investigated differences in pain responsiveness within a group of patients with genetic FTD. Changes in pain responsiveness compared to baseline were captured using a scale designed by the group, and patients were scored from 0-3 (0 = no change, 0.5 = questionable or very mild change, 1 = mild change, 2 = moderate change, 3 = severe change). Within the sample, symptomatic C9orf72 mutation carriers (9/31) experienced greater changes in pain responsiveness than symptomatic MAPT (1/10) and GRN (1/24) mutation-carriers or normal controls (1/181). Within the C9orf72 mutation carriers, these changes were associated with thalamo-cortico-striatal atrophy.
    This research brings attention to an important but little-investigated clinical feature of FTD. Changes in pain responsiveness, including both increases and decreases, have now been reported in both sporadic and genetic FTD, along with other somatic complaints.[1–4] However, the changes are not widely captured in either clinical or research settings, and the field lacks standardized and objective measurements to do so. The ability to measure changes in pain responsiveness may be a useful clinical marker to di...

    Show More
    Conflict of Interest:
    None declared.